Search results
2 lip 2021 · An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care. Pharmacogenomics J. 2019;19:480–9.
- Pharmacogenomic testing for antidepressant treatment selection: lessons ...
Pharmacogenomic decision support tools are an evolving...
- Pharmacogenomic testing for antidepressant treatment selection: lessons ...
31 sty 2020 · One included systematic review reported the probability of pharmacogenomics testing being cost-effective at the willingness to pay threshold of $50,000 was 94.5%. One 9 of the three included economic evaluations reported the lack of conclusion on cost-effectiveness of screening for CYP2D6 in primary care patients using antidepressants. Two ...
14 lis 2023 · Through a combination of higher remission rates and lower discontinuation rates, pharmacogenomic testing resulted in 23 216 (37%) fewer patients developing refractory depression; this was the main driver of cost savings.
26 lis 2022 · Our analysis uses clinical patient outcome data from Bradley et al and published health care costs to model the cost savings associated with pharmacogenetic-guided treatment for depression in Psychiatry, Internal Medicine, Obstetrics & Gynecology, and Family Medicine clinics.
Cost. The costs associated with pharmacogenomic testing differ across tests and can be affected by factors such as the methods of sample collection (e.g., blood drawn versus self-collected saliva), the complexity of genetic analysis (e.g., single gene versus multigene), and how the test results are communicated. 48,49.
Medication management guided by pharmacogenetics has been shown to increase therapeutic eficacy and improve symptoms in patients diagnosed with depression, but limited data are available on the cost savings of pharmacogenetic-guided interventions outside of psychiatric clinical specialties.
7 sie 2023 · Pharmacogenomic decision support tools are an evolving technology that help clinicians make informed decisions, based on clinically actionable genetic variants in pharmacokinetic (PK) and or...
